Cited by 252HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Open access

Dave, Bhuvanesh, Migliaccio, Ilenia, Gutierrez, M. Carolina, Wu, Meng-Fen, Chamness, Gary C., Wong, Helen, Narasanna, Archana, Chakrabarty, Anindita, Hilsenbeck, Susan G., Huang, Jian, Rimawi, Mothaffar, Schiff, Rachel, Arteaga, Carlos, Osborne, C. Kent, Chang, Jenny C.·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.7814PMC PMC3058274

Open this paper in CoChat — free account

Abstract

PURPOSE: Phosphatase and tensin homolog (PTEN) loss or activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab resistance. Trastuzumab, the humanized human epidermal growth factor receptor 2 (HER2) monoclonal antibody, and lapatinib, an epidermal growth factor receptor/HER2 tyrosine kinase inhibitor, are both established treatments for HER2-overexpressing breast cancers. Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit. METHODS: We evaluated the effect of trastuzumab or lapatinib in three HER2-overexpressing cell lines. We confirmed the in vitro observations in two neoadjuvant clinical trials in patients with HER2 overexpression; 35 patients received trastuzumab as a single agent for the first 3 weeks, then docetaxel every 3 weeks for 12 weeks (trastuzumab regimen), whereas 49 patients received lapatinib as a single agent for 6 weeks, followed by trastuzumab/docetaxel for 12 weeks before primary surgery (lapatinib regimen). Apoptosis, Ki67, p-MAPK, p-AKT, and PTEN were assessed by immunohistochemistry. Genomic DNA was sequenced for PIK3CA mutations. RESULTS: Under low PTEN conditions, in vitro data indicate that lapatinib alone and in combination with trastuzumab was effective in decreasing p-MAPK and p-AKT levels, whereas trastuzumab was ineffective. In the clinical trials, we confirmed that low PTEN or activating mutation in PIK3CA conferred resistance to the trastuzumab regimen (P = .015), whereas low PTEN tumors were associated with a high pathologic complete response rate (P = .007). CONCLUSION: Activation of PI3 kinase pathway is associated with trastuzumab resistance, whereas low PTEN predicted for response to lapatinib. These observations support clinical trials with the combination of both agents.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.7814

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutiérrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A. C., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,789
Self-citation
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,023
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 8

Rusnak DW, 2001, Cancer Res, 61, 7196
DeSimone PA, 2002, Proc Am Soc Clin Oncol, 21, 34a
10.1200/jco.2004.22.14_suppl.3006 · DOI
10.1200/jco.2004.22.14_suppl.3188 · DOI
Allred DC, 1998, Mod Pathol, 11, 155
Bacus SS, 1992, Cancer Res, 52, 2580
Peng D, 1996, Cancer Res, 56, 3666
Ben-Bassat H, 1997, Cancer Res, 57, 3741

Sorted by citations

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,324
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Self-citation
Cancer Stem Cell Metabolism
Peiris-Pagès, M., Martinez-Outschoorn, U. E., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0712-6 · Cited by 465
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465
Self-citation
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Carey, L., Berry, D. A., Cirrincione, C., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
Brooks, M., Burness, M. L., & Wicha, M. S. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.014 · Cited by 383
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 377
Self-citation
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 386
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Hurvitz, S. A., André, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 311
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutiérrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
Self-citation
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 272
Self-citation
Therapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L. M., & Miller, T. W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 246
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
Majewski, I. J., Nuciforo, P. G., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E. M., Sotiriou, C. P., Fumagalli, D., Jimenez, J., Aura, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 239
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
Gallardo, A., Lerma, E., Escuín, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 234
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 202
Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 186
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. ‐., Augustin, D., Küemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx494 · Cited by 167
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Gu, G., Dustin, D., & Fuqua, S. A. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.005 · Cited by 163
Gastric cancer: somatic genetics as a guide to therapy
Zhang, X., & Zhang, P.-Y. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104171 · Cited by 159
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
Fumagalli, D., Venet, D., Ignatiadis, M., Azim, H. A., Maetens, M., Rothé, F., Salgado, R., Bradbury, I., Pusztai, L., Harbeck, N., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3824 · Cited by 151
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 149
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
Bazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., Milella, M., & Ciuffreda, L. (2019) · Cancers · doi:10.3390/cancers11040435 · Cited by 151
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
Xia, W., Petricoin, E., Zhao, S., Liu, L.-H., Osada, T., Cheng, Q., Wulfkuhle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3480 · Cited by 143
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Self-citation
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 135
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Jensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 135
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Kim, J., Fox, C., Peng, S., Pusung, M., Pectasides, E., Matthée, E., Hong, Y. S., Do, I., Jang, J., Thorner, A. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75200 · Cited by 133
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors
Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130
Self-citation
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes
Marusyk, A., Tabassum, D. P., Janiszewska, M., Place, A. E., Trinh, A. C., Rozhok, A. I., Pyne, S., Guerriero, J. L., Shu, S., Ekram, M. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1457 · Cited by 129
Self-citation
The Breast Cancer Stem Cells Traits and Drug Resistance
Zheng, Q., Zhang, M., Zhou, F., Zhang, L., & Meng, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.599965 · Cited by 133
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 125
Self-citation
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 121
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 119
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
Lima, Z. S., Ghadamzadeh, M., Arashloo, F. T., Amjad, G., Ebadi, M. R., & Younesi, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0725-6 · Cited by 123
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Giuliano, M., Hu, H., Wang, Y.-C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutiérrez, C., Wang, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2728 · Cited by 118
Self-citation
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L. Y., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2014) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 110
PIK3R1 underexpression is an independent prognostic marker in breast cancer
Čížková, M., Vacher, S., Meseure, D., Trassard, M., Susini, A., Mlcuchova, D., Callens, C., Rouleau, É., Spyratos, F., Lidereau, R., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-545 · Cited by 111
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
Pogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 111
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Lauring, J. D., Park, B. H., & Wolff, A. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0086 · Cited by 114
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
Guarneri, V., Dieci, M. V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S. R., Tagliafico, E., Bicciato, S., Generali, D., Cagossi, K., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0138 · Cited by 109
Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival
Baker, A. T., Wyatt, D. L., Bocchetta, M., Li, J., Filipović, A., Green, A. R., Peiffer, D. S., Fuqua, S. A. W., Miele, L., Albain, K. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0251-y · Cited by 108
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity
Huang, Y., Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0510-3 · Cited by 110
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2642 · Cited by 106
Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
Krop, I. E., & Winer, E. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0541 · Cited by 105
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 106
Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer
Bardia, A., & Baselga, J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0916 · Cited by 102
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 99
Self-citation
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Rimawi, M. F., Angelis, C. D., Contreras, A., Pareja, F. G., Geyer, F. C., Burke, K. A., Herrera, S., Wang, T., Mayer, I. A., Forero, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4533-9 · Cited by 98
Self-citation
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Ling, Y., Liang, G., Lin, Q., Fang, X., Luo, Q., Cen, Y., Mehrpour, M., Hamaï, A., Liu, Z., Shi, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01476-7 · Cited by 97
β2-AR signaling controls trastuzumab resistance-dependent pathway
Liu, D., Yang, Z., Wang, T., Yang, Z., Chen, H., Hu, Y., Hu, C., Guo, L., Deng, Q., Liu, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.58 · Cited by 97
Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
Kechagioglou, P., Papi, R. M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, P., Nonni, A., Zografos, G., Kyriakidis, D. A., & Gounaris, A. (2014) · PubMed · Cited by 95
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Smith, A. E., Ferraro, E., Safonov, A. M., Morales, C. B., Arenas, E. J., Li, Q., Kulick, A. R., Ross, D. S., Solit, D. B., de Stanchina, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27093-y · Cited by 99
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Howe, L. R., & Brown, P. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0334 · Cited by 93
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
Cizkova, M., Dujaric, M. E., Lehmann‐Che, J., Scott, V., Tembo, O., Asselain, B. J. R., Pierga, J., Marty, M. E., de Crémoux, P., Spyratos, F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.164 · Cited by 90
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
Sharial, M. S. N. M., Crown, J. P., & Hennessy, B. T. (2012) · Annals of Oncology · doi:10.1093/annonc/mds200 · Cited by 90
HSP90 as a platform for the assembly of more effective cancer chemotherapy
Whitesell, L. J., & Lin, N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.12.006 · Cited by 85
Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications
Zhou, J., Chen, Q., Zou, Y., Chen, H., Qi, L., & Chen, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00820 · Cited by 84
Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
Cufí, S., Vázquez‐Martín, A., Oliveras‐Ferraros, C., Corominas-Faja, B., Urruticoechea, A., Martı́n-Castillo, B., & Menéndez, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.742 · Cited by 75
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
Alba, E., Albanell, J., de la Haba-Rodríguez, J., Barnadas, A., Calvo, L., Sánchez‐Rovira, P., Ramos, M., Rojo, F., Burgués, O., Carrasco, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.831 · Cited by 73
Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
Schrock, A. B., Pavlick, D. C., Klempner, S. J., Chung, J., Forcier, B., Welsh, A. W., Young, L., Leyland-Jones, B., Bordoni, R. E., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 71
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 75
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer
Sheri, A., & Dowsett, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds307 · Cited by 68
Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells
Pande, S., Browne, G., Padmanabhan, S., Zaidi, S. K., Lian, J. B., van Wijnen, A. J., Stein, J. L., & Stein, G. S. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24339 · Cited by 67
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
Veeraraghavan, J., Angelis, C. D., Reis-Filho, J. S., Pascual, T., Prat, A., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2017) · The Breast · doi:10.1016/j.breast.2017.06.022 · Cited by 67
Self-citation
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
De, P. K. R., Hasmann, M., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.006 · Cited by 66
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T. A., Ensor, J., Creamer, S. L., Boone, T., Rodriguez, A. A., Niravath, P. A., Darcourt, J. G., Meisel, J. L., Li, X., Zhao, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1186-0 · Cited by 66
Self-citation
Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
Guarneri, V., Generali, D., Frassoldati, A., Artioli, F., Boni, C., Cavanna, L., Tagliafico, E., Maiorana, A., Bottini, A., Cagossi, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4737 · Cited by 61
Targeting the PI3K Pathway for Cancer Therapy
Sadeghi, N., & Gerber, D. E. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.56 · Cited by 59
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
Okines, A. F. C., & Cunningham, D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12450246 · Cited by 60
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Crawford, A. C., & Nahta, R. (2011) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569211796957584 · Cited by 55
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
Ramirez-Ardila, D. E., Helmijr, J., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., Laere, S. V., Dirix, L. Y., Sweep, F. C. G. J., Span, P. N., Linn, S. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2529-7 · Cited by 53
Biomarkers of drugs targeting HER ‐family signalling in cancer
Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 56
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis
Wang, Y., Liu, Y., Du, Y., Yin, W., & Lu, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794775 · Cited by 53
Resistance to Anti-HER2 Therapies in Breast Cancer
Rimawi, M. F., Angelis, C. D., & Schiff, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e157 · Cited by 52
Self-citation
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
Wetterskog, D., Shiu, K.-K., Chong, I. Y.-S., Meijer, T. G., Mackay, A. G., Lambros, M. B. K., Cunningham, D., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2013) · Oncogene · doi:10.1038/onc.2013.41 · Cited by 51
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
Santarpia, L., Bottai, G., Kelly, C. M., Győrffy, B., Székely, B., & Pusztai, L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0369 · Cited by 59
Integrin α3β1–CD151 complex regulates dimerization of ErbB2 via RhoA
Novitskaya, V., Romańska, H., Kordek, R., Potemski, P., Kusińska, R., Parsons, M., Odintsova, E., & Berditchevski, F. (2013) · Oncogene · doi:10.1038/onc.2013.231 · Cited by 50
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett, J. T., Chakrabarty, A., & Arteaga, C. L. (2011) · Oncotarget · doi:10.18632/oncotarget.409 · Cited by 49
Self-citation
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
Farrugia, M. K., Sharma, S. B., Lin, C.-C., McLaughlin, S. L., Vanderbilt, D. B., Ammer, A. G., Salkeni, M. A., Stoilov, P., Agazie, Y. M., Creighton, C. J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.65 · Cited by 49
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Yuan, H., Chen, J., Liu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3354 · Cited by 45
Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib
Luca, A. D., D’Alessio, A., Gallo, M., Maiello, M. R., Bode, A. M., & Normanno, N. (2013) · Cell Cycle · doi:10.4161/cc.26899 · Cited by 44
The Role of PTEN in Tumor Angiogenesis
Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44
Advances in systemic therapy for metastatic breast cancer: future perspectives
Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., & Generali, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0975-5 · Cited by 44
Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
Khokhar, N. Z., Altman, J. K., & Platanias, L. C. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834b892d · Cited by 43
The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics
Scott, J. M., Gilchrist, S. C., Mackey, J. R., Douglas, P. S., Haykowsky, M. J., & Jones, L. W. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0226 · Cited by 44
Inhibition of Cell Proliferation and Metastasis by Scutellarein Regulating PI3K/Akt/NF-κB Signaling through PTEN Activation in Hepatocellular Carcinoma
Ha, S. E., Kim, S. M., Vetrivel, P., Kim, H. H., Bhosale, P. B., Heo, J., Lee, H. J., & Kim, G. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168841 · Cited by 45
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan, J., Angelis, C. D., Mao, R., Wang, T., Herrera, S., Pavlick, A. C., Contreras, A., Nuciforo, P. G., Mayer, I. A., Forero-Torres, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz076 · Cited by 42
Self-citation
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Nuciforo, P. G., Aura, C. M., Holmes, E. M., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Peña, L., Ellis, C., Eidtmann, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv175 · Cited by 41
Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
Yin, W., Wang, Y., Wu, Z., Ye, Y., Zhou, L., Xu, S., Lin, Y., Du, Y., Yan, T., Yang, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0446 · Cited by 41
Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40
Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway
Liu, G., Zhou, J., & Dong, M. (2019) · Bioscience Reports · doi:10.1042/bsr20190249 · Cited by 40
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria
Harlé, A., Lion, M., Lozano, N., Husson, M., Harter, V., Génin, P., & Merlin, J. (2013) · Oncology Reports · doi:10.3892/or.2013.2229 · Cited by 40
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
Leblanc, O., Vacher, S., Lecerf, C., Jeannot, E., Klijanienko, J., Berger, F., Hoffmann, C., Calugaru, V., Badois, N., Chilles, A., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0153 · Cited by 38
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
Liu, X., Song, Y., Cheng, P., Liang, B., & Xing, D. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102826 · Cited by 37
Molecular markers for breast cancer diagnosis, prognosis and targeted therapy
Lang, J. E., Wecsler, J. S., Press, M. F., & Tripathy, D. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23732 · Cited by 37
Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
Sachdev, J. C., & Jahanzeb, M. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.001 · Cited by 37

Authors: Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., Rimawi, M., Schiff, R., Arteaga, C., Osborne, C. K., & Chang, J. C.
Affiliations: Houston Methodist (US)
ORCID: Migliaccio, Ilenia
Wu, Meng-Fen
Wong, Helen
Chakrabarty, Anindita
Hilsenbeck, Susan G.
Huang, Jian
Rimawi, Mothaffar
Schiff, Rachel
Arteaga, Carlos
Osborne, C. Kent
Chang, Jenny C.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-01-10
Volume: 29
Issue: 2
Pages: 166-173
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.7814
PMC: PMC3058274
OpenAlex: W2109189228
Cited by: 252
References: 28
Citations by year: 2026: 1 · 2025: 10 · 2024: 7 · 2023: 15 · 2022: 10 · 2021: 7 · 2020: 12 · 2019: 14 · 2018: 10 · 2017: 17 · 2016: 15 · 2015: 32 · 2014: 21 · 2013: 34 · 2012: 21
FWCI: 12.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Breast Cancer Research Foundation
GlaxoSmithKline
National Cancer Institute (P50 CA 50183, R01CA112305)
Medical Research and Materiel Command
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: PTEN loss, PIK3CA mutation, trastuzumab resistance, lapatinib, HER2-positive breast cancer, locally advanced breast cancer, PI3 kinase pathway, MAPK signaling, Akt phosphorylation, pathological complete response, neoadjuvant therapy
MeSH terms: Trastuzumab, Docetaxel, Lapatinib, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Enzyme Activation, Female, Humans, Middle Aged, Mutation, Quinazolines, Transfection, Clinical Trials, Phase II as Topic, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Phosphatidylinositol 3-Kinases, Neoadjuvant Therapy, RNA, Small Interfering, Taxoids, Cell Line, Tumor, PTEN Phosphohydrolase, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks